Long‐term protection of macaques against high‐dose type D retrovirus challenge after immunization with recombinant vaccinia virus expressing envelope glycoproteins

Publisher Website
Google Scholar
Abstract
Recombinant vaccinia virus expressing the envelope proteins of type D retrovirus‐Washington (SRV‐2/W) was used to immunize macaques against SRV‐2 infection. Four immunized macaques which had resisted a prior low‐dose challenge were rechallenged with a high dose (10” infectious particles) of SRV‐2 two years after being immunized. All four non‐immunized control macaques became infected, but the four vaccinated animals resisted this intravenous challenge, as determined by the inability to detect SRV‐2 in peripheral blood mononuclear cells and by the lack of seroconversion to new viral antigens.
Funding Information
  • U.S. Public Health Service
  • National Institutes of Health (N01‐74102, RR00166)